Suspension of ulipristal acetate for uterine fibroids during ongoing EMA’s review of liver injury risk: Unfortunate timing during the Covid-19 pandemic!

[1]  S. Corrao,et al.  COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review , 2020, Clinics and practice.

[2]  Charlotte Martin,et al.  Are we equal in adversity? Does Covid-19 affect women and men differently? , 2020, Maturitas.

[3]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[4]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[5]  M. Nisolle,et al.  Effect on surgical decisions: Ulipristal acetate as key player in Belgian phase IV registration trial , 2019, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[6]  J. Vandromme,et al.  The use of selective progestin receptor modulators (SPRMs) and more specifically ulipristal acetate in the practice of gynaecology , 2017, The Australian & New Zealand journal of obstetrics & gynaecology.

[7]  D. Baird,et al.  A single baseline ultrasound assessment of fibroid presence and size is strongly predictive of future uterine procedure: 8-year follow-up of randomly sampled premenopausal women aged 35-49 years. , 2015, Human reproduction.

[8]  Dawn L Hershman,et al.  Failure to rescue after major gynecologic surgery. , 2013, American journal of obstetrics and gynecology.

[9]  I. Osterloh,et al.  Ulipristal acetate versus placebo for fibroid treatment before surgery. , 2012, The New England journal of medicine.

[10]  J. Vandromme,et al.  Medical or surgical management of fibroids? An internet survey of gynecologists' views. , 2017, Maturitas.

[11]  L. Shulman.  Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery , 2012 .